Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gold, Ralf, Comi, Giancarlo, Palace, Jacqueline, Siever, Arno, Gottschalk, Rebecca, Bijarnia, Mahendra, von Rosenstiel, Philipp, Tomic, Davorka, Kappos, Ludwig
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2013
Gaiak:
Original Communication
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3915082/
https://ncbi.nlm.nih.gov/pubmed/24221641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-013-7115-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak